NASH and Quality of Life
Prof Schattenberg, Germany, reviews how NASH impacts quality of life. He presents the mechanisms underlying metabolic comorbidities in NASH and discusses the relevant NASH phenotypes.
Video NASH and Quality of Life -Copyright ©2023 by PanNash™ Initiative - All rights reserved.
A presentation of the tools that can be used to review health-related quality of life (HQRL) is particularly relevant for clinicians.
NASH impacts quality of life. It is important to review the mechanisms underlying metabolic comorbidities in NASH and the relevant NASH phenotypes.
Would you like to read more?
Prof. Dr. Jörn M. Schattenberg
Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD) has emerged as a leading cause…
Advancing Fibrosis Imaging: An Evaluation of Radiotracer Efficacy
Tissue fibrosis is induced by an excessive collagen deposition in organs suffering from inflammation and is associated with several diseases,…
Global research on fatty liver disease: a review
In this study, a large, global, multidisciplinary panel discussed priorities within the field of fatty liver disease, including its burden,…
Discerning sex-related differences in NAFLD patients via metabolic profiling
Research into personalised medicine for non-alcoholic fatty liver disease (NAFLD) underscores the importance of acknowledging NAFLD patients’ unique clinical phenotypes…
The Long Road to NASH Therapeutics: Uncovering Valuable Insights
Recent research indicates that 30% of adults worldwide, 90% of those with obesity, and 70% with type 2 diabetes are…
NAFLD and Pancreatic Steatosis: A Bidirectional Relationship?
Recent research supports the existence of a potential link between non-alcoholic fatty liver disease (NAFLD) and fatty pancreas.
NIS2+™: an effective blood-based test for the detection of at-risk NASH in older adults?
At-risk non-alcoholic steatohepatitis (NASH) is defined as NASH with NAFLD activity scores (NAS) ≥4 and significant fibrosis (F ≥ 2)…
Are Non-invasive Tools Less Accurate in NAFLD Patients With Type 2 Diabetes?
Recent literature on non-alcoholic fatty liver disease (NAFLD) has sought to characterise its bidirectional association with type 2 diabetes mellitus…
Understanding Nash: Symptoms, Detection, And Treatment
Nonalcoholic steatohepatitis (NASH), the progressive form of nonalcoholic fatty liver disease (NAFLD), has seen a consistent rise in prevalence in…
Ballooning Hepatocytes In Nash: Mechanisms, Implications, And Technological Advances
Hepatocytic ballooning is characterised by hepatocyte degeneration identifiable through an enlarged, swollen and rounded cellular phenotype with a distinctly reticulated…
Lifestyle interventions in NAFLD: what does the evidence say?
Despite an estimated global prevalence of 38%, no pharmacotherapy has yet been approved for non-alcoholic fatty liver disease (NAFLD).
NASH Progression and Clinical Outcomes: Defining Predictive LSM-VCTE Thresholds
In patients with non-alcoholic steatohepatitis (NASH), the risk of liver-related mortality and decompensation is known to increase proportionally with fibrosis…
SUBSCRIBE & FOLLOW US
Subscribe Our Newsletter To Get the Lastest Updates
